vs
Side-by-side financial comparison of PCB BANCORP (PCB) and ZEVRA THERAPEUTICS, INC. (ZVRA). Click either name above to swap in a different company.
ZEVRA THERAPEUTICS, INC. is the larger business by last-quarter revenue ($34.1M vs $29.2M, roughly 1.2× PCB BANCORP). On growth, ZEVRA THERAPEUTICS, INC. posted the faster year-over-year revenue change (183.4% vs 11.3%). PCB BANCORP produced more free cash flow last quarter ($24.4M vs $5.5M). Over the past eight quarters, ZEVRA THERAPEUTICS, INC.'s revenue compounded faster (215.7% CAGR vs 10.4%).
PCB Bank is an American community bank that focuses on the Korean-American community based in California and offers commercial banking services. It has branches in 8 states and is the third largest Korean American Bank after Bank of Hope and Hanmi Bank.
Zevra Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients with rare under-treated orphan diseases, with a primary focus on central nervous system and metabolic rare disorder segments. Its main target markets are North America and the European Union.
PCB vs ZVRA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $29.2M | $34.1M |
| Net Profit | — | — |
| Gross Margin | — | — |
| Operating Margin | 45.0% | 27.3% |
| Net Margin | — | — |
| Revenue YoY | 11.3% | 183.4% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.65 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $29.2M | $34.1M | ||
| Q3 25 | $30.4M | $26.1M | ||
| Q2 25 | $29.3M | $25.9M | ||
| Q1 25 | $26.9M | $20.4M | ||
| Q4 24 | $26.2M | $12.0M | ||
| Q3 24 | $25.3M | $3.7M | ||
| Q2 24 | $24.2M | $4.4M | ||
| Q1 24 | $23.9M | $3.4M |
| Q4 25 | — | — | ||
| Q3 25 | $11.4M | $-544.0K | ||
| Q2 25 | $9.1M | $74.7M | ||
| Q1 25 | $7.7M | $-3.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | $7.8M | $-33.2M | ||
| Q2 24 | $6.3M | $-19.9M | ||
| Q1 24 | $4.7M | $-16.6M |
| Q4 25 | 45.0% | 27.3% | ||
| Q3 25 | 52.3% | 15.9% | ||
| Q2 25 | 43.3% | -274.5% | ||
| Q1 25 | 40.2% | -26.3% | ||
| Q4 24 | 39.3% | -128.0% | ||
| Q3 24 | 42.2% | -739.0% | ||
| Q2 24 | 36.3% | -534.8% | ||
| Q1 24 | 27.2% | -598.1% |
| Q4 25 | — | — | ||
| Q3 25 | 37.5% | -2.1% | ||
| Q2 25 | 31.0% | 288.7% | ||
| Q1 25 | 28.8% | -15.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | 30.8% | -899.2% | ||
| Q2 24 | 25.9% | -447.9% | ||
| Q1 24 | 19.6% | -485.3% |
| Q4 25 | $0.65 | — | ||
| Q3 25 | $0.78 | $-0.01 | ||
| Q2 25 | $0.62 | $1.21 | ||
| Q1 25 | $0.53 | — | ||
| Q4 24 | $0.46 | — | ||
| Q3 24 | $0.52 | $-0.69 | ||
| Q2 24 | $0.43 | $-0.48 | ||
| Q1 24 | $0.33 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $207.1M | $62.4M |
| Total DebtLower is stronger | — | $61.9M |
| Stockholders' EquityBook value | $390.0M | $154.7M |
| Total Assets | $3.3B | $284.7M |
| Debt / EquityLower = less leverage | — | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $207.1M | $62.4M | ||
| Q3 25 | $369.5M | $54.4M | ||
| Q2 25 | $263.6M | $47.7M | ||
| Q1 25 | $214.3M | $37.3M | ||
| Q4 24 | $198.8M | $33.8M | ||
| Q3 24 | $193.1M | $54.0M | ||
| Q2 24 | $177.6M | $39.3M | ||
| Q1 24 | $239.8M | $42.8M |
| Q4 25 | — | $61.9M | ||
| Q3 25 | — | $61.3M | ||
| Q2 25 | — | $60.7M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $59.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $390.0M | $154.7M | ||
| Q3 25 | $384.5M | $133.2M | ||
| Q2 25 | $376.5M | $117.2M | ||
| Q1 25 | $370.9M | $41.0M | ||
| Q4 24 | $363.8M | $39.7M | ||
| Q3 24 | $362.3M | $69.8M | ||
| Q2 24 | $353.5M | $32.5M | ||
| Q1 24 | $350.0M | $48.8M |
| Q4 25 | $3.3B | $284.7M | ||
| Q3 25 | $3.4B | $270.1M | ||
| Q2 25 | $3.3B | $256.3M | ||
| Q1 25 | $3.2B | $172.7M | ||
| Q4 24 | $3.1B | $178.1M | ||
| Q3 24 | $2.9B | $191.6M | ||
| Q2 24 | $2.9B | $144.4M | ||
| Q1 24 | $2.9B | $151.3M |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.50× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $26.6M | $5.5M |
| Free Cash FlowOCF − Capex | $24.4M | $5.5M |
| FCF MarginFCF / Revenue | 83.6% | 16.1% |
| Capex IntensityCapex / Revenue | 7.5% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $46.0M | $-2.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $26.6M | $5.5M | ||
| Q3 25 | $16.4M | $4.7M | ||
| Q2 25 | $4.9M | $-3.6M | ||
| Q1 25 | $2.3M | $-8.2M | ||
| Q4 24 | $39.0M | $-16.3M | ||
| Q3 24 | $11.9M | $-18.1M | ||
| Q2 24 | $14.6M | $-19.1M | ||
| Q1 24 | $8.2M | $-16.2M |
| Q4 25 | $24.4M | $5.5M | ||
| Q3 25 | $16.2M | $4.2M | ||
| Q2 25 | $3.8M | $-3.8M | ||
| Q1 25 | $1.6M | $-8.3M | ||
| Q4 24 | $34.9M | — | ||
| Q3 24 | $11.9M | — | ||
| Q2 24 | $12.8M | — | ||
| Q1 24 | $6.0M | — |
| Q4 25 | 83.6% | 16.1% | ||
| Q3 25 | 53.2% | 15.9% | ||
| Q2 25 | 13.1% | -14.7% | ||
| Q1 25 | 6.0% | -40.8% | ||
| Q4 24 | 133.2% | — | ||
| Q3 24 | 46.8% | — | ||
| Q2 24 | 53.1% | — | ||
| Q1 24 | 25.2% | — |
| Q4 25 | 7.5% | 0.1% | ||
| Q3 25 | 0.8% | 2.1% | ||
| Q2 25 | 3.7% | 0.8% | ||
| Q1 25 | 2.8% | 0.5% | ||
| Q4 24 | 15.5% | 0.0% | ||
| Q3 24 | 0.1% | 0.0% | ||
| Q2 24 | 7.3% | 0.0% | ||
| Q1 24 | 9.3% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 0.54× | -0.05× | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 2.33× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCB
Segment breakdown not available.
ZVRA
| MIPLYFFA | $26.4M | 77% |
| Arimoclomol Purchase Agreement | $5.7M | 17% |
| Other | $2.0M | 6% |
